IRIS
CAMELI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.290
EU - Europa 15.287
AS - Asia 8.150
SA - Sud America 1.424
Continente sconosciuto - Info sul continente non disponibili 1.015
AF - Africa 513
OC - Oceania 43
AN - Antartide 1
Totale 41.723
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.909
IT - Italia 4.654
RU - Federazione Russa 3.295
SG - Singapore 2.693
CN - Cina 1.910
GB - Regno Unito 1.827
IE - Irlanda 1.658
BR - Brasile 1.174
VN - Vietnam 1.049
DE - Germania 847
HK - Hong Kong 824
SE - Svezia 746
FR - Francia 682
FI - Finlandia 510
IN - India 381
KR - Corea 308
ZA - Sudafrica 272
BD - Bangladesh 232
CA - Canada 202
NL - Olanda 202
UA - Ucraina 202
ES - Italia 166
JP - Giappone 116
IQ - Iraq 104
MX - Messico 100
PL - Polonia 98
CZ - Repubblica Ceca 78
TR - Turchia 70
CI - Costa d'Avorio 62
AT - Austria 61
AR - Argentina 60
PK - Pakistan 59
EC - Ecuador 50
ID - Indonesia 46
NG - Nigeria 44
IR - Iran 41
SA - Arabia Saudita 39
CH - Svizzera 36
VE - Venezuela 36
KE - Kenya 35
BE - Belgio 34
AU - Australia 33
PH - Filippine 32
MA - Marocco 30
UZ - Uzbekistan 29
CO - Colombia 27
LT - Lituania 26
AE - Emirati Arabi Uniti 25
CL - Cile 22
MY - Malesia 21
EG - Egitto 19
PY - Paraguay 19
JO - Giordania 18
PE - Perù 18
AZ - Azerbaigian 16
DK - Danimarca 16
JM - Giamaica 16
HU - Ungheria 15
PT - Portogallo 15
RO - Romania 15
BG - Bulgaria 14
IL - Israele 14
TN - Tunisia 14
KZ - Kazakistan 13
AL - Albania 12
DZ - Algeria 12
NP - Nepal 12
LB - Libano 11
BO - Bolivia 10
PA - Panama 10
GR - Grecia 9
KG - Kirghizistan 9
CR - Costa Rica 8
GE - Georgia 8
MK - Macedonia 8
NZ - Nuova Zelanda 8
OM - Oman 8
BY - Bielorussia 7
CY - Cipro 7
EE - Estonia 7
GT - Guatemala 7
LV - Lettonia 7
PS - Palestinian Territory 7
SN - Senegal 7
TH - Thailandia 7
TT - Trinidad e Tobago 7
EU - Europa 6
HN - Honduras 6
LA - Repubblica Popolare Democratica del Laos 6
LK - Sri Lanka 6
UY - Uruguay 6
DO - Repubblica Dominicana 5
HR - Croazia 5
NO - Norvegia 5
QA - Qatar 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
AM - Armenia 4
IS - Islanda 4
KW - Kuwait 4
Totale 40.639
Salva come PNG Salva come JPEG
Città #
Dallas 2.921
Dublin 1.627
Singapore 1.585
Southend 1.442
Ashburn 1.187
San Jose 1.032
Moscow 991
Santa Clara 980
Milan 954
Hong Kong 762
Fairfield 731
Chandler 716
Council Bluffs 641
Siena 500
Beijing 496
Hefei 455
Los Angeles 408
Munich 368
Rome 355
Helsinki 340
Woodbridge 323
New York 319
Ho Chi Minh City 318
Lastra a Signa 314
Houston 312
Wilmington 307
Florence 293
Seattle 286
Seoul 280
Johannesburg 243
Hanoi 240
Princeton 230
Cambridge 229
Lauterbourg 222
The Dalles 171
Ann Arbor 146
São Paulo 120
Columbus 112
Jacksonville 112
Shanghai 104
Chicago 103
Buffalo 91
Orem 91
Redondo Beach 85
Tokyo 85
Bengaluru 83
Warsaw 82
Frankfurt am Main 77
San Mateo 77
Turku 76
Dong Ket 75
Lappeenranta 73
London 73
San Diego 72
Fremont 71
Málaga 68
Nuremberg 63
Abidjan 62
Boardman 62
Chennai 61
Düsseldorf 59
Phoenix 59
Figino 58
Turin 56
Da Nang 54
Montreal 54
Naples 54
Portsmouth 53
Atlanta 52
Dearborn 51
Toronto 51
Brooklyn 48
Boston 47
Stockholm 47
Brno 44
Rio de Janeiro 44
Manchester 40
Washington 40
Bologna 39
Denver 39
Haiphong 39
Baghdad 36
Amsterdam 34
Brescia 34
Poplar 34
Abuja 33
Mexico City 32
San Francisco 32
Guangzhou 31
Vienna 31
Dhaka 29
Miami 28
Mumbai 27
Newark 27
Paris 27
Gavirate 26
Tashkent 26
Brasília 25
Charlotte 24
Olomouc 24
Totale 26.290
Salva come PNG Salva come JPEG
Nome #
A first update on mapping the human genetic architecture of COVID-19 601
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 592
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 534
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 508
Genetic mechanisms of critical illness in COVID-19 452
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 440
An explainable model of host genetic interactions linked to COVID-19 severity 386
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 382
Pathogen-sugar interactions revealed by universal saturation transfer analysis 374
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 367
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 356
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 355
Mapping the human genetic architecture of COVID-19 325
Peripheral biomarkers' panel for severe COVID-19 patients 323
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 319
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 313
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 312
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 309
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 307
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 304
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 302
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 290
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 284
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 283
ACUTE HF score, a multiparametric prognostic tool for acute heart failure: A real-life study 280
Exhaled nitric oxide in interstitial lung diseases 278
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 275
The impact of antifibrotic therapy in the management of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world comparative study of efficacy between pirfenidone and nintedanib 275
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 271
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 269
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 264
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 260
Prognostic bioindicators in severe COVID-19 patients 258
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 258
Serial KL-6 measurements in COVID-19 patients 253
Incremental value of pocket-sized imaging device for bedside diagnosis of unilateral pleural effusions and ultrasound-guided thoracentesis 252
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 252
Omalizumab treatment in Samter's triad: case series and review of the literature 251
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 250
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 248
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 247
Serum amyloid A in patients with idiopathic pulmonary fibrosis 246
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 245
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 242
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 240
Comparison of Right Versus Left Ventricular Strain Analysis as a Predictor of Outcome in Patients With Systolic Heart Failure Referred for Heart Transplantation 238
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 237
NK and NKT-like cells in granulomatous and fibrotic lung diseases 232
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 232
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 232
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 231
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 230
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 229
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 229
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 229
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 228
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 228
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 227
Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings 227
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 224
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 220
Whole-genome sequencing reveals host factors underlying critical COVID-19 218
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 217
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 216
Portable Pocket-Sized Ultrasound Scanner for the Evaluation of Lung Involvement in Coronavirus Disease 2019 Patients 215
WES profiling of COVID-19 215
Serum amyloid A: A potential biomarker of lung disorders 210
Clinical and molecular characterization of COVID-19 hospitalized patients 207
Traditional and Novel Imaging of Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction 205
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 205
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 204
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 203
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 202
Severe asthma and long-term Benralizumab effectiveness in real-life 201
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 201
Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication 200
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 199
Effects of rituximab therapy on B cell differentiation and depletion 197
Basic and advanced echocardiography in advanced heart failure: an overview 195
Left atrial strain as a pre-operative prognostic marker for patients with severe mitral regurgitation 191
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 191
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 188
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 188
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 188
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 188
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 187
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 186
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 186
Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study 185
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 184
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 183
The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study 182
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 182
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 182
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 182
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 179
Bone fragility and sarcoidosis: An underestimated relationship 178
Timing of Osteoporotic Vertebral Fractures in Lung and Heart Transplantation: A Longitudinal Study 178
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 178
Echocardiography for left ventricular assist device implantation and evaluation: an indispensable tool 173
Totale 25.674
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.432
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.432
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.366 0 281 225 182 124 114 110 118 114 321 269 508
2022/20233.028 200 342 390 305 186 521 261 265 210 123 127 98
2023/20243.392 132 93 328 173 170 737 956 193 56 119 127 308
2024/20257.932 607 312 846 453 960 485 452 458 644 394 729 1.592
2025/202619.229 1.279 2.445 2.254 2.176 3.399 642 2.287 600 739 1.300 704 1.404
2026/20271.348 788 560 0 0 0 0 0 0 0 0 0 0
Totale 41.723